- Recruiting
RADAR (UK-MRA Myeloma XV): treatment escalation and de-escalation strategies in NDMM - TE Myeloma
Updated: Oct 23, 2022
RADAR (UK-MRA Myeloma XV): Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell transplant (TE).
RADAR (UK-MRA Myeloma XV): Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell transplant (TE).
EudraCT Number: 2019-001258-25
National Competent Authority: UK - MHRA
Full title of the trial
Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell transplant (TE).
Name of Sponsor
University of Leeds
Cancer Research UK
Sanofi (isatuximab) and Celgene (lenalidomide)
Sanofi S.A
Celgene Corporation
RADAR (UK-MRA Myeloma XV)
EudraCT Number: 2019-001258-25
A phase II and phase III trial comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma suitable for stem cell transplant (TE)
Date on which this record was first entered in the EudraCT database: 2020-03-18
https://www.ukmf.org.uk/wp-content/uploads/2020/11/RP-UKMF21_Trials-update.pdf
Treatment Agents | Myeloma Clinical Trials (themyelomaclinicaltrials.com)
Locations
Europe
United Kingdom